@article{ref1,
title="sustained virologic response and adverse effects of peg interferon alfa and ribavirin in the treatment of patients with chronic hepatitis c: a study from Iran",
journal="Novelty Biomed.",
year="2017",
author="Simin, Shoaei and Shahnaz, Sali and Azadeh, Lali and Mehdi, Karamipour and Javad, Minooeefar",
volume="5",
number="4",
pages="172-176",
abstract="BACKGROUND: Hepatitis C infection is a worldwide problem. In Iran, hepatitis C virus [HCV] infection prevalence is about 1-2%. A combination therapy of pegylated interferon alfa-2a and ribavirin [PEG-IFNalpha/RBV] is a standard treatment, but our aim was to determine the efficacy and safety of dual PEG-IFNalpha/RBV therapy in treating patients infected with HCV in Iranian context<p /><p>Language: en</p>",
language="en",
issn="2345-3346",
doi="",
url="http://dx.doi.org/"
}